Summit Therapeutics (SMMT) Misses Q2 EPS by 3c
Tweet
Share
E-mail
Summit Therapeutics (NASDAQ: SMMT) reported Q2 EPS of (GBP0.12), GBP0.03 worse than the analyst estimate of (GBP0.09).
For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- JPMorgan Starts Kanzhun Ltd (2076:HK) at Overweight
- RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
